Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
15 p, 594.2 KB A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy : results from FIRE-3 and JACCRO 05 and 06 trials / Sebio, A. (Institut d'Investigació Biomèdica Sant Pau) ; Stintzing, S. (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich,) ; Heinemann, V. (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich,) ; Sunakawa, Y. (Keck School of Medicine, University of Southern California) ; Zhang, W. (Keck School of Medicine, University of Southern California) ; Ichikawa, W. (Division of Medical Oncology, Showa University) ; Tsuji, A. (Department of Clinical Oncology, Kagawa University) ; Takahashi, T. (Division of Medical Oncology, Showa University) ; Parek, A. (Keck School of Medicine, University of Southern California) ; Yang, D. (Keck School of Medicine, University of Southern California) ; Cao, S. (Keck School of Medicine, University of Southern California) ; Ning, Y. (Keck School of Medicine, University of Southern California) ; Stremitzer, S. (Keck School of Medicine, University of Southern California) ; Matsusaka, S. (Keck School of Medicine, University of Southern California) ; Okazaki, S. (Keck School of Medicine, University of Southern California) ; Barzi, A. (Keck School of Medicine, University of Southern California) ; Berger, M. (Keck School of Medicine, University of Southern California) ; Lenz, H-J (Keck School of Medicine, University of Southern California)
The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested single nucleotide polymorphisms within Hippo components and their association with outcome in CRC patients treated with cetuximab. [...]
2016 - 10.1038/tpj.2016.69
The pharmacogenomics journal, october 2016  
2.
22 p, 644.2 KB Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer / Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Matsusaka, Satoshi (Keck School of Medicine, University of Southern California) ; Zhang, Wu (Keck School of Medicine, University of Southern California) ; Yang, Dongyun (Keck School of Medicine, University of Southern California) ; Ning, Yan (Keck School of Medicine, University of Southern California) ; Stremitzer, Stefan (Keck School of Medicine, University of Southern California) ; Stintzing, Sebastian (Department of Hematology and Oncology, Klinikum der Universitat, University of Munich, Munich, Germany) ; Sunakawa, Yu (Keck School of Medicine, University of Southern California) ; Yamauchi, Shinichi (Keck School of Medicine, University of Southern California) ; Fujimoto, Yoshiya (Cancer Institute Hospital. Department of Gastroenterological Surgery (Tokyo)) ; Ueno, Masashi (Cancer Institute Hospital. Department of Gastroenterological Surgery (Tokyo)) ; Lenz, Heinz-Josef (Keck School of Medicine, University of Southern California)
The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil. In this study 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. [...]
2015 - 10.1038/tpj.2015.64
The pharmacogenomics journal, Vol. 16 (september 2015) , p. 312-319  

Vegeu també: autors amb noms similars
1 Stintzing, Sebastian
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.